Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622409 | 0.84 | LMNA (0.56) | HTTSMN1; SMN2CES2CES1KMT2A | |
| SCHEMBL10622910 | 0.83 | CYP1A2 (0.44) | HTTSMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL1259916 | 0.83 | ESRRG (0.46) | HTTSMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL7701905 | 0.83 | ALDH1A1 (0.53) | HTTSMN1; SMN2CES2CES1KMT2A | |
| SCHEMBL14648650 | 0.82 | TDP1 (0.48) | HTTKMT2AMEN1LMNAMAPT | |
| SCHEMBL2071460 | 0.82 | ALDH1A1 (0.50) | SMN1; SMN2KMT2AMEN1MAPTGAA | |
| SCHEMBL21006684 | 0.82 | HDAC1 (0.58) | HTTCES2CES1KMT2ALMNA | |
| SCHEMBL27778655 | 0.82 | CYP1A2 (0.52) | MAPTGAAL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL30187429 | 0.81 | GSK3B (0.61) | HTTSMN1; SMN2CES2CES1KMT2A | |
| SCHEMBL3269069 | 0.81 | HTT (0.50) | HTTSMN1; SMN2CES2CES1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105669747-A | Preparing method of alpha-hydroxy phosphate | 苏州大学张家港工业技术研究院 | 2016-06-15 | — | — | CN | claimed |
| CN-108558813-B | Resveratrol derivative containing flavonoid as well as preparation method and application thereof | 合肥工业大学 | 2021-07-23 | — | — | CN | disclosed |
| CN-105669747-A | Preparing method of alpha-hydroxy phosphate | 苏州大学张家港工业技术研究院 | 2016-06-15 | — | — | CN | disclosed |
| CN-102796086-A | Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof | ABBOTT LAB | 2012-11-28 | — | — | CN | disclosed |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-12-17 | — | — | US | disclosed |
| US-7560558-B2 | Compound having TGFβ inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-07-14 | — | — | US | disclosed |
| CN-101426498-A | Antagonists of vanilloid receptor subtype 1 (VR 1) and uses thereof | ABBOTT LAB (US) | 2009-05-06 | — | — | CN | disclosed |
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1548008-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-29 | — | — | EP | disclosed |
| EP-1133467-B1 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH AS (DK) | 2004-09-15 | — | — | EP | disclosed |
| EP-1133467-A1 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2001-09-19 | — | — | EP | disclosed |
| EP-1109800-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LIMITED (KR) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000034228-A1 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000012496-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LTD. (KR) | 2000-03-09 | — | — | WO | disclosed |
| EP-0246114-B1 | PHOTOCHROMIC SPIROPYRAN COMPOUNDS | GEC-MARCONI LIMITED (GB) | 1992-09-02 | — | — | EP | disclosed |
| US-4826977-A | Photochromic spiropyran compounds | THE PLESSEY COMPANY PLC (GB) | 1989-05-02 | — | — | US | disclosed |
| EP-0246114-A2 | Photochromic spiropyran compounds | GEC-MARCONI LIMITED (GB) | 1987-11-19 | — | — | EP | disclosed |
| US-4122256-A | OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-24 | — | — | US | disclosed |
| US-4052433-A | INTERMEDIATES FOR BENZOFURANS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-10-04 | — | — | US | disclosed |
| US-3994879-A | CONDENSING AZOMETHINES, OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | TGFB1, TGFBR1, TGFBR2 | HTT 4107/4885SMN1; SMN2 3891/4885CES2 4312/4885 |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TGFB1, TGFBR1, TGFBR2 | HTT 3446/4885SMN1; SMN2 3772/4885CES2 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.